Clients in the media Clients IN the MEDIA

Ensuring your story is visible.
BioProcessOnline

Gene Therapy For Chronic Inflammation With Xalud’s Howard Rutman, M.D.

While many gene therapy development efforts focus on rare disease, Xalud Therapeutics is taking a swing that, measured in addressable patient market terms, is considerably bigger.

2023 Finance And Funding Outlook: Additional Insights Part 2

With pipeline and patent expiration pressures, large pharmaceutical companies will need to strategically acquire or align with biotechnology companies providing potential solutions to core asset life cycle management, as well as accessing proprietary assets to address pipeline gaps.

biospace

Setting the Stage for ASH 2022

On Monday, Elixirgen Therapeutics and its research collaborators will present data from the company’s lead candidate, EXG-34217, a first-in-human cell therapy that aims to extend telomere length in patients with telomere biology disorders.

BioProcessOnline

Gene Therapy For Chronic Inflammation With Xalud’s Howard Rutman, M.D.

While many gene therapy development efforts focus on rare disease, Xalud Therapeutics is taking a swing that, measured in addressable patient market terms, is considerably bigger.

pharma shots

Tim Clackson, President & CEO of Theseus Pharmaceuticals, Shares Insights on its Pan-Variant Inhibitor Therapies to Treat Cancer

Theseus’ pan-variant inhibitor candidates are designed to outsmart cancer treatment resistance by precluding that “arms race.” Pan-variant inhibitors are single therapeutic agents that maintain their anti-cancer activity against a target protein in the face of any and all major classes of cancer-causing and resistance mutations.

biospace

Recession Survival Strategies for Newly Public Biopharma Companies

PepGen was one of a handful of biotech companies to go public this year, tapping into capital markets despite high inflation and economic conditions that have leading analysts predicting a global recession throughout 2023.

Longevity Technology

Magnetic field tech captures the ‘song’ of a drug

The concept behind EMulate’s approach is mind-boggling. The company “records” the electromagnetic signature of specific molecules and is then able to use those recordings to effect changes in cellular behaviour, without using chemicals. In its most advanced programme, EMulate’s technology has completed feasibility clinical trials for adults and children with terminal brain cancer, using a recording derived from chemotherapy drug paclitaxel. We caught up with EMulate’s CEO Chris Rivera to find out more.

How Sernova seeks to treat insulin-dependent diabetes with its Cell Pouch System

When Dr. Philip Toleikis joined Sernova in 2009, the company’s technology appeared as more of a concept than anything else. But, he saw the potential for something groundbreaking: